Motco Has $7.65 Million Stock Holdings in Stryker Co. (NYSE:SYK)

Motco raised its stake in Stryker Co. (NYSE:SYKGet Rating) by 1.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 28,621 shares of the medical technology company’s stock after buying an additional 307 shares during the quarter. Motco’s holdings in Stryker were worth $7,653,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Patriot Financial Group Insurance Agency LLC increased its stake in shares of Stryker by 6.3% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 645 shares of the medical technology company’s stock worth $172,000 after purchasing an additional 38 shares during the last quarter. First Foundation Advisors increased its stake in shares of Stryker by 4.8% during the 3rd quarter. First Foundation Advisors now owns 893 shares of the medical technology company’s stock worth $236,000 after purchasing an additional 41 shares during the last quarter. Community Capital Management LLC increased its stake in shares of Stryker by 2.2% during the 4th quarter. Community Capital Management LLC now owns 2,000 shares of the medical technology company’s stock worth $523,000 after purchasing an additional 44 shares during the last quarter. Capital Investment Advisors LLC increased its stake in shares of Stryker by 4.5% during the 4th quarter. Capital Investment Advisors LLC now owns 1,037 shares of the medical technology company’s stock worth $277,000 after purchasing an additional 45 shares during the last quarter. Finally, Bellwether Advisors LLC increased its stake in shares of Stryker by 7.4% during the 3rd quarter. Bellwether Advisors LLC now owns 685 shares of the medical technology company’s stock worth $180,000 after purchasing an additional 47 shares during the last quarter. Institutional investors own 73.61% of the company’s stock.

Several research analysts have recently commented on the stock. SVB Leerink dropped their price target on shares of Stryker from $300.00 to $285.00 and set an “outperform” rating on the stock in a research note on Friday, January 28th. Piper Sandler decreased their price objective on shares of Stryker from $315.00 to $290.00 in a report on Friday. StockNews.com started coverage on shares of Stryker in a report on Thursday, March 31st. They set a “buy” rating for the company. Truist Financial started coverage on shares of Stryker in a report on Tuesday, April 12th. They set a “hold” rating and a $296.00 price objective for the company. Finally, BTIG Research upped their price objective on shares of Stryker from $273.00 to $278.00 in a report on Monday, April 18th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $292.33.

Shares of SYK stock traded down $10.84 during mid-day trading on Friday, reaching $241.26. The company’s stock had a trading volume of 3,090,497 shares, compared to its average volume of 1,507,806. Stryker Co. has a 1-year low of $236.09 and a 1-year high of $281.16. The company has a market cap of $91.12 billion, a P/E ratio of 45.87, a PEG ratio of 2.78 and a beta of 0.98. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.47 and a current ratio of 2.20. The firm’s 50-day moving average is $261.04 and its two-hundred day moving average is $260.68.

Stryker (NYSE:SYKGet Rating) last announced its quarterly earnings data on Thursday, April 28th. The medical technology company reported $1.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.95 by $0.02. Stryker had a net margin of 11.65% and a return on equity of 24.65%. The company had revenue of $4.30 billion during the quarter, compared to analysts’ expectations of $4.19 billion. During the same quarter in the prior year, the company posted $1.93 EPS. The business’s revenue was up 8.8% on a year-over-year basis. Sell-side analysts anticipate that Stryker Co. will post 9.72 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, April 29th. Stockholders of record on Thursday, March 31st were paid a $0.695 dividend. This represents a $2.78 dividend on an annualized basis and a dividend yield of 1.15%. The ex-dividend date was Wednesday, March 30th. Stryker’s dividend payout ratio is 52.85%.

Stryker Profile (Get Rating)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies.

Recommended Stories

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYKGet Rating).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.